The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2023 | Approaching patients with MDS and AML who relapse after alloSCT & strategies to prevent relapse
Pramila Krishnamurthy, MA, FRCPath, MRCP, PhD, King’s College Hospital NHS Foundation Trust, London, UK, discusses approaches to prevent relapse in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) after allogeneic stem cell transplantation (alloSCT). Dr Krishnamurthy explains that patients with a high risk of relapse may benefit from pre-emptive or prophylactic donor lymphocyte infusion (DLI). Dr Krishnamurthy further discusses studies evaluating agents such as azacitidine, magrolimab, eprenetapopt, and venetoclax in this patient group. This interview took place at the 63rd Annual Scientific Meeting of the British Society for Haematology (BSH) 2023, held in Birmingham, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: Astellas, Stemline Menarini, Janssen, Abbvie, Gilead
